CN111053823A - A Chinese medicinal composition for regulating hypertension, and its preparation method - Google Patents
A Chinese medicinal composition for regulating hypertension, and its preparation method Download PDFInfo
- Publication number
- CN111053823A CN111053823A CN202010066360.7A CN202010066360A CN111053823A CN 111053823 A CN111053823 A CN 111053823A CN 202010066360 A CN202010066360 A CN 202010066360A CN 111053823 A CN111053823 A CN 111053823A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- weight
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition granule for regulating hypertension and a preparation method thereof. The invention provides a traditional Chinese medicine composition for regulating hypertension, which comprises the following raw materials in parts by weight: 10-15 parts of American ginseng, 10-15 parts of astragalus membranaceus, 10-15 parts of apocynum venetum, 10-12 parts of motherwort fruit, 5-8 parts of kudzu root, 5-8 parts of cassia seed and 5-8 parts of wolfberry fruit. The Chinese medicinal composition has remarkable effect, and can be taken for a long time.
Description
Technical Field
The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for regulating hypertension and a preparation method thereof.
Background
Hypertension (hypertension) is a clinical syndrome characterized by an increase in systemic arterial blood pressure (systolic pressure and/or diastolic pressure) (systolic pressure not less than 140 mm hg, diastolic pressure not less than 90 mm hg), and may be accompanied by functional or organic damage to organs such as heart, brain, kidney, etc. Hypertension is the most common chronic disease and also the most major risk factor for cardiovascular and cerebrovascular diseases. The blood pressure of a normal person fluctuates within a certain range along with the changes of internal and external environments. In the whole population, the blood pressure level gradually increases with age, the systolic pressure is more obvious, but the diastolic pressure shows a descending trend after the age of 50, and the pulse pressure is increased. The symptoms of hypertension vary from person to person. Early stage may be asymptomatic or symptoms are not obvious, and dizziness, headache, neck and neck plate tightness, fatigue, palpitation and the like are common. Elevation of blood pressure occurs only after exertion, mental stress, mood swings, and returns to normal after rest. With the prolonged course of disease, the blood pressure is obviously and continuously increased, and various symptoms gradually appear. This is called a progressive hypertension. Common clinical symptoms of the slow-advancing hypertension include headache, dizziness, inattention, hypomnesis, numbness of limbs, nocturia, palpitation, chest distress, hypodynamia and the like. The symptoms of hypertension are related to blood pressure level, most symptoms can be aggravated after tension or fatigue, blood pressure can be rapidly increased after activities in the early morning, and early-morning hypertension appears, so that cardiovascular and cerebrovascular events are frequently occurred in the early morning.
The hypertension is affected by various reasons, such as about 60 percent of hypertension patients have family history, the hypertension is considered to be caused by polygenic inheritance at present, 30 to 50 percent of hypertension patients have genetic background, the hypertension is caused by long-term mental stress, excitement, anxiety, noise or poor visual stimulation, the dietary structure is unreasonable, the hypertension can be increased by excessive sodium salt, low-potassium diet, a large amount of drinking and excessive saturated fatty acid, the atherosclerosis process can be accelerated by smoking, the hypertension is a risk factor, and the like.
Disclosure of Invention
Aiming at the problems, the invention provides a traditional Chinese medicine composition for regulating hypertension and a preparation method thereof. The Chinese medicinal composition has remarkable effect, and can be taken for a long time.
In order to achieve the purpose, the traditional Chinese medicine composition for regulating hypertension provided by the invention comprises the following raw materials in parts by weight: 10-15 parts of American ginseng, 10-15 parts of astragalus membranaceus, 10-15 parts of apocynum venetum, 10-12 parts of motherwort fruit, 5-8 parts of kudzu root, 5-8 parts of cassia seed and 5-8 parts of wolfberry fruit.
In order to achieve the above purpose, the preparation method of the traditional Chinese medicine composition for regulating hypertension provided by the invention specifically comprises the following steps: the preparation method comprises the steps of taking the traditional Chinese medicine raw materials according to the parts by weight, adding water with the mass of 5-6 times of the traditional Chinese medicine materials, decocting for 3 times, 30-40min each time, filtering, combining the decoctions, concentrating to liquid medicine with the weight of 1.5-2 times of the total weight of the traditional Chinese medicine raw materials, and preparing into corresponding dosage forms.
The composition can be prepared into clinically acceptable formulations such as tea, granules, powder, tablets and the like.
Analyzing the drug properties of the raw materials.
American ginseng: cool in nature, sweet and slightly bitter in taste; it has effects in regulating blood pressure, lowering temporary or permanent blood pressure, lowering blood coagulability, inhibiting platelet aggregation, resisting atherosclerosis, and promoting erythrocyte growth.
Astragalus root: sweet in nature, slightly warm in taste, entering lung, spleen, liver and kidney meridians; has effects in reducing blood viscosity, reducing adhesion in blood vessel, and preventing thrombosis.
And (3) bluish dogbane: sweet and bitter in nature, cool in flavor, entering liver meridian; has the effects of calming the liver, soothing the nerves, clearing heat and promoting diuresis; modern researches have proved that the pharmacological components have the effects of lowering blood pressure and reducing blood fat.
Motherwort fruit: pungent, bitter and slightly cold; clearing away heat and toxic material, inducing diuresis to alleviate edema, promoting blood circulation and activating qi-flowing.
Kudzu root: sweet and pungent in flavor, cool in nature, entering lung and stomach meridians; the kudzu root has certain functions of relaxing blood vessels and reducing blood pressure; puerarin has obvious curative effect on headache, dizziness, tinnitus and other symptoms caused by blood pressure.
Cassia seed: cassia seed, bitter, sweet, salty and slightly cold in nature, enters liver, kidney and large intestine meridians; loosening bowel to relieve constipation, reducing blood lipid, improving eyesight, and treating constipation, hyperlipemia, and hypertension. Clearing liver-fire, improving eyesight, promoting diuresis, relaxing bowels, lowering blood pressure, and reducing blood lipid.
Wolfberry fruit: sweet in nature and mild in taste; can reduce the content of malondialdehyde and endothelin in blood plasma and blood vessel, increase the release of calcitonin gene related peptide, and prevent hypertension.
The invention has remarkable effect.
The formula of the invention is an effective medicine for regulating hypertension; the invention is safe, nontoxic, cheap and practical. The components of the composition all belong to a list of traditional Chinese medicines published by the national ministry of health, which are both foods and medicines, are safe and nontoxic, and are suitable for long-term administration; after the product is taken, the blood pressure can be effectively reduced, and the product is safe and has no toxic or side effect.
The invention has clear compatibility, and the compatibility principle of the invention is as follows: the American ginseng and the astragalus root are used as monarch drugs, and the main component of the American ginseng is ginsenoside, so that the American ginseng and the astragalus root can regulate blood pressure, dilate blood vessels, effectively reduce temporary and persistent blood pressure and help to adjust hypertension to a normal state; radix astragali is a medicine for tonifying qi and invigorating yang, but is sweet in nature and warm in taste, and can obviously reduce blood viscosity and reduce attachments in blood vessels when being used together with American ginseng, so that thrombosis is prevented. Studies show that after 2 hours of stomach filling of the apocynum venetum leaf decoction for the hypertensive dog, the blood pressure is reduced from 194/142 mm Hg to 152/100 mm Hg and is stabilized at a lower level all the time, and the blood pressure rises after 3 days; motherwort fruit, named ' Shunqi Huo Xue, nourishing liver and benefiting heart, Anhui Ding (soul) and ' Chang Xue Jie (blood circulation is very quick) '; the Qing Dynasty, He Ben Li (the nature of the drugs in the affairs) indicates clearly that it is effective in removing blood stasis and promoting tissue regeneration; motherwort fruit is used for treating hypertension in mr, and the primary medicine is motherwort fruit. The apocynum venetum and the motherwort fruit are adopted in the formula together with the drug effect of the monarch drug, so that the optimal blood pressure stabilizing effect of the formula is achieved. The kudzuvine root, the cassia seed and the medlar are used as adjuvants, the kudzuvine root has certain functions of relaxing blood vessels and reducing blood pressure, and has obvious curative effects on symptoms such as headache, dizziness, tinnitus and the like caused by the blood pressure; the pharmacological action of the cassia seeds is mainly shown in the aspects of reducing blood pressure, reducing blood fat, relaxing the bowels and the like, and animal experiments show that the water extract and the alcohol-water extract of the cassia seeds have the function of reducing blood pressure for anesthetized cats and dogs; fructus Lycii can reduce the content of malondialdehyde and endothelin in blood plasma and blood vessel, increase the release of calcitonin gene related peptide, and prevent hypertension. The adjuvant has the function of obviously relieving the symptoms caused by the hypertension.
Detailed Description
The present invention will be described in detail with reference to specific examples.
Example 1.
The traditional Chinese medicine tea for regulating the hypertension comprises the following raw materials in parts by weight: 8 parts of American ginseng, 12 parts of astragalus, 10 parts of apocynum venetum, 10 parts of motherwort fruit, 8 parts of kudzu root, 5 parts of cassia seed and 5 parts of medlar.
The preparation method of the traditional Chinese medicine composition for regulating the hypertension specifically comprises the following steps: the traditional Chinese medicine raw materials are taken according to the parts by weight, added with water with the weight 6 times of that of the traditional Chinese medicine materials and decocted for 3 times, each time for 38min, filtered, the decocted liquid is merged and concentrated to liquid medicine with the weight 1.8 times of the total weight of the traditional Chinese medicine raw materials, and the corresponding tea preparation is prepared.
Example 2.
The traditional Chinese medicine granules for regulating the hypertension comprise the following raw materials in parts by weight: 10 parts of American ginseng, 10 parts of astragalus, 12 parts of apocynum venetum, 12 parts of motherwort fruit, 5 parts of kudzu root, 8 parts of cassia seed and 8 parts of medlar.
Example 3.
The traditional Chinese medicine powder for regulating hypertension comprises the following raw materials in parts by weight: 15 parts of American ginseng, 15 parts of astragalus, 115 parts of apocynum venetum, 12 parts of motherwort fruit, 5 parts of kudzu root, 6 parts of cassia seed and 7 parts of medlar.
First, pharmacodynamic and toxicity test: in order to prove the curative effect and the safety of the medicament, the inventor conducts pharmacodynamic and toxicity test investigation; the test method and test results are as follows:
the purpose of the test is as follows: the traditional Chinese medicine preparation for regulating hypertension has the function of reducing blood pressure of rats with primary hypertension.
Test materials: medicine preparation: examples 1-3 Chinese medicinal preparations for regulating hypertension; nifedipine tablets. Animals: selecting 50 primary hypertension rats purchased from the experimental animal center of Hubei Chinese medicine university, wherein the weight is 200-; feeding in positive pressure purified ventilated animal room at room temperature of 25 + -2 deg.C, and freely taking food and drinking water.
Test methods and results: the test rats were placed in a pressure measuring cell for 2 weeks of training and blood pressure was measured every other day on the second week (mean 3 measurements per day); the animals are placed in an electric heating box at 37 +/-1 ℃ for heating before the manometry, and the rat systolic pressure is measured by a rat sphygmomanometer after 15 minutes.
The primary hypertension rats are randomly divided into 5 groups, namely 3 groups of the drug experimental group, 10 groups of the drug positive control group and 10 groups of the drug model group; the experimental group of the medicine takes the traditional Chinese medicine preparation prepared in the embodiments 1-3 of the invention orally (10g crude drugs/kg); a positive control group oral nifedipine tablet oral liquid (10 mg/kg); the model control group was orally administered the same volume of distilled water once a day for 5 weeks. The feeding, activity and excretion of the mice in each group were observed during and before the administration period, and no abnormal condition occurred. The systolic blood pressure of the rats was measured 3 times at 1, 2, 3, 4, and 5 weeks after the administration, and the mean value was taken. The blood pressure measurement time after the administration was performed 2 hours after the administration, and the measurement was completed within 5 hours after the administration.
Statistical analysis is carried out by adopting SPSS software, test results are all expressed by x +/-s, ANOVA variance analysis is adopted for multi-group mean comparison, and q test is adopted for inter-group comparison; p is less than or equal to 0.05, and the difference has significance; the test results are shown in Table 1.
TABLE 1 statistical results (unit: mmHg) of measurements of systolic blood pressure of primary hypertensive rats 5 times consecutively after 1 week of administration.
Note: comparison with model groups: p < 0.05; comparison with control 1:△△P＜0.05。
the experimental data in table 1 show that: after 1 week of administration, the blood pressure of the primary hypertension rat taking the traditional Chinese medicine preparation prepared by the invention begins to drop and continues to stop at the end of the 4 th week, and the blood pressure drops to a value similar to a normal value and is basically equal to the blood pressure value of a positive control group; compared with the rat blood pressure contraction value of the model control group, the blood pressure contraction value of the rat is reduced by nearly 40mm Hg, and the experimental statistical data of the drug group is less than 0.05 relative to the model control group, so that the drug group has significant difference. The traditional Chinese medicine composition for reducing blood pressure has quick response and good curative effect on reducing blood pressure.
Claims (6)
1. A traditional Chinese medicine composition for regulating hypertension is characterized by comprising the following raw materials in parts by weight: 10-15 parts of American ginseng, 10-15 parts of astragalus membranaceus, 10-15 parts of apocynum venetum, 10-12 parts of motherwort fruit, 5-8 parts of kudzu root, 5-8 parts of cassia seed and 5-8 parts of wolfberry fruit.
2. The traditional Chinese medicine composition for regulating hypertension according to claim 1, which is prepared from the following raw materials in parts by weight: 8 parts of American ginseng, 12 parts of astragalus, 10 parts of apocynum venetum, 10 parts of motherwort fruit, 8 parts of kudzu root, 5 parts of cassia seed and 5 parts of medlar.
3. The traditional Chinese medicine composition for regulating hypertension according to claim 1, which is prepared from the following raw materials in parts by weight: 10 parts of American ginseng, 10 parts of astragalus, 12 parts of apocynum venetum, 12 parts of motherwort fruit, 5 parts of kudzu root, 8 parts of cassia seed and 8 parts of medlar.
4. The traditional Chinese medicine composition for regulating hypertension according to claim 1, which is prepared from the following raw materials in parts by weight: 15 parts of American ginseng, 15 parts of astragalus, 115 parts of apocynum venetum, 12 parts of motherwort fruit, 5 parts of kudzu root, 6 parts of cassia seed and 7 parts of medlar.
5. The Chinese medicinal composition for regulating hypertension according to any one of claims 1 to 4, wherein the composition is in the form of tea, granules, powder or tablets.
6. The method for preparing a Chinese medicinal composition for regulating hypertension according to any one of claims 1 to 4, which specifically comprises: the preparation method comprises the steps of taking the traditional Chinese medicine raw materials according to the parts by weight, adding water with the mass of 5-6 times of the traditional Chinese medicine materials, decocting for 3 times, 30-40min each time, filtering, combining the decoctions, concentrating to liquid medicine with the weight of 1.5-2 times of the total weight of the traditional Chinese medicine raw materials, and preparing into corresponding dosage forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010066360.7A CN111053823A (en) | 2020-01-20 | 2020-01-20 | A Chinese medicinal composition for regulating hypertension, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010066360.7A CN111053823A (en) | 2020-01-20 | 2020-01-20 | A Chinese medicinal composition for regulating hypertension, and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111053823A true CN111053823A (en) | 2020-04-24 |
Family
ID=70307697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010066360.7A Pending CN111053823A (en) | 2020-01-20 | 2020-01-20 | A Chinese medicinal composition for regulating hypertension, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111053823A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557382A (en) * | 2004-02-11 | 2004-12-29 | 武汉化工学院 | Glucoside compound preparation and its preparing process |
| CN1623409A (en) * | 2003-12-07 | 2005-06-08 | 黄衍强 | Beverage made of cassia seed fruit of Chinese wolfbeery and honey and its preparation method |
| CN101491331A (en) * | 2008-01-23 | 2009-07-29 | 邓喆铭 | Natural health beverage and manufacture method thereof |
| CN102631405A (en) * | 2012-05-10 | 2012-08-15 | 西北农林科技大学 | Compound apigenin nanoemulsion antihypertensive drug |
| CN103141635A (en) * | 2013-03-07 | 2013-06-12 | 王玉兰 | Fried semen cassia and apocynum venetum tea |
| CN105432870A (en) * | 2014-09-29 | 2016-03-30 | 吴同忠 | Cassia seed-wolfberry tea for treating hypertension |
| CN107467315A (en) * | 2017-09-28 | 2017-12-15 | 山西中医药大学 | A kind of tea for reducing hypertension and fat and preparation method thereof |
| CN109938135A (en) * | 2019-04-12 | 2019-06-28 | 孟庆菊 | A kind of cassia seed tea-drinking and preparation method thereof |
| CN110538311A (en) * | 2019-08-20 | 2019-12-06 | 刘德平 | Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof |
-
2020
- 2020-01-20 CN CN202010066360.7A patent/CN111053823A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1623409A (en) * | 2003-12-07 | 2005-06-08 | 黄衍强 | Beverage made of cassia seed fruit of Chinese wolfbeery and honey and its preparation method |
| CN1557382A (en) * | 2004-02-11 | 2004-12-29 | 武汉化工学院 | Glucoside compound preparation and its preparing process |
| CN101491331A (en) * | 2008-01-23 | 2009-07-29 | 邓喆铭 | Natural health beverage and manufacture method thereof |
| CN102631405A (en) * | 2012-05-10 | 2012-08-15 | 西北农林科技大学 | Compound apigenin nanoemulsion antihypertensive drug |
| CN103141635A (en) * | 2013-03-07 | 2013-06-12 | 王玉兰 | Fried semen cassia and apocynum venetum tea |
| CN105432870A (en) * | 2014-09-29 | 2016-03-30 | 吴同忠 | Cassia seed-wolfberry tea for treating hypertension |
| CN107467315A (en) * | 2017-09-28 | 2017-12-15 | 山西中医药大学 | A kind of tea for reducing hypertension and fat and preparation method thereof |
| CN109938135A (en) * | 2019-04-12 | 2019-06-28 | 孟庆菊 | A kind of cassia seed tea-drinking and preparation method thereof |
| CN110538311A (en) * | 2019-08-20 | 2019-12-06 | 刘德平 | Pure traditional Chinese medicine composition for controlling hypertension and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 周卫凤，等: "丹芪葛根汤对自发性高血压大鼠心肌AngⅡ含量的影响", 《中国中医药科技》 * |
| 李丽，等: "钱海凌教授运用温法治疗老年高血压病经验总结", 《四川中医》 * |
| 田燕，主编: "《一味中药降血压》", 31 January 2018, 河南科学技术出版社 * |
| 董瑞馨，等: "探讨中药"四味饮方"用于原发性高血压病的疗效", 《中国实用护理杂志》 * |
| 黄骏: "葛根槐茺汤治疗高血压病50例", 《湖北中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101277710B (en) | Antiobesity composition | |
| CN101011561B (en) | Modern traditional Chinese medicine oral preparation huanglianwendan decoction and production method thereof | |
| CN103027138B (en) | Tea for enlivening spleens and production method of tea | |
| CN102293927B (en) | Compound Chinese medicinal preparation with antifatigue and antioxidation effects, and preparation method thereof | |
| CN112546167A (en) | Traditional Chinese medicine composition with spleen invigorating and dampness removing functions and preparation method and application thereof | |
| CN101085079B (en) | Traditional Chinese medicine compound for treating diabetes and its preparation method and application | |
| CN101732491B (en) | Medicament for treating hypertension, hyperlipoidemia, high blood viscosity and anti-aging | |
| CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
| CN102940730A (en) | Traditional Chinese medicine for treating hypertension | |
| CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
| KR101910013B1 (en) | A composition for improving, preventing and treating of pain comprising herb extract | |
| CN106177054A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Pericarpium Citri Reticulatae | |
| CN111053823A (en) | A Chinese medicinal composition for regulating hypertension, and its preparation method | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN103525640B (en) | Energy-keeping yang-tonifying wine | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN105343506A (en) | Method for preparing composition for treating type-2 diabetes | |
| CN105560984B (en) | Traditional Chinese medicine composition capable of boosting qi and invigorating spleen | |
| KR20080056927A (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
| CN116440224B (en) | Traditional Chinese medicine composition, preparation and preparation method | |
| CN109106842B (en) | A medicine for stopping smoking and its preparation method | |
| CN108403803B (en) | Chinese medicinal compound preparation for preventing and treating cardiovascular complications of diabetes | |
| CN105250417A (en) | Pharmaceutical composition for treating diarrheic type irritable bowel syndrome and application thereof | |
| CN113229498A (en) | Medicinal and edible composition formula conducive to blood pressure reduction and preparation process thereof | |
| CN104940693A (en) | Dendrobium officinale traditional Chinese medicine composition capable of lowering three highs and preparation method of dendrobium officinale traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200424 |
|
| WD01 | Invention patent application deemed withdrawn after publication |